+

EE200200522A - Toimeainega konjugeerunud ensüüm-lõhustuv peptiid, seda sisaldav farmatseutiline kompositsioon ningühendi kasutamine kasvajavastase ravimina - Google Patents

Toimeainega konjugeerunud ensüüm-lõhustuv peptiid, seda sisaldav farmatseutiline kompositsioon ningühendi kasutamine kasvajavastase ravimina

Info

Publication number
EE200200522A
EE200200522A EEP200200522A EEP200200522A EE200200522A EE 200200522 A EE200200522 A EE 200200522A EE P200200522 A EEP200200522 A EE P200200522A EE P200200522 A EEP200200522 A EE P200200522A EE 200200522 A EE200200522 A EE 200200522A
Authority
EE
Estonia
Prior art keywords
enzyme
pharmaceutical composition
active ingredient
composition containing
antitumor drug
Prior art date
Application number
EEP200200522A
Other languages
English (en)
Estonian (et)
Inventor
A. Copeland Robert
F. Albright Charles
P. Combs Andrew
L. Dowling Randine
R. Graciani Nilsa
Han Wei
Anne Higley C.
S. Huang Pearl
W. Yue Eddy
V. Dimeo Susan
Original Assignee
Bristol-Myers Squibb Pharma Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Pharma Company filed Critical Bristol-Myers Squibb Pharma Company
Publication of EE200200522A publication Critical patent/EE200200522A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EEP200200522A 2000-03-15 2001-03-15 Toimeainega konjugeerunud ensüüm-lõhustuv peptiid, seda sisaldav farmatseutiline kompositsioon ningühendi kasutamine kasvajavastase ravimina EE200200522A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18938700P 2000-03-15 2000-03-15
PCT/US2001/008589 WO2001068145A2 (en) 2000-03-15 2001-03-15 Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use

Publications (1)

Publication Number Publication Date
EE200200522A true EE200200522A (et) 2004-04-15

Family

ID=22697116

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200522A EE200200522A (et) 2000-03-15 2001-03-15 Toimeainega konjugeerunud ensüüm-lõhustuv peptiid, seda sisaldav farmatseutiline kompositsioon ningühendi kasutamine kasvajavastase ravimina

Country Status (19)

Country Link
US (1) US6844318B2 (xx)
EP (1) EP1263473A2 (xx)
JP (1) JP2003526683A (xx)
KR (1) KR20030009388A (xx)
CN (1) CN1418112A (xx)
AU (2) AU2001245836A1 (xx)
BR (1) BR0109266A (xx)
CA (1) CA2401873A1 (xx)
CZ (1) CZ20022998A3 (xx)
EE (1) EE200200522A (xx)
HU (1) HUP0300590A2 (xx)
IL (1) IL151400A0 (xx)
MX (1) MXPA02009019A (xx)
NO (1) NO20024238D0 (xx)
PL (1) PL360826A1 (xx)
RU (1) RU2002127425A (xx)
SK (1) SK12872002A3 (xx)
TR (1) TR200202183T2 (xx)
WO (1) WO2001068145A2 (xx)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115573B2 (en) 2000-06-14 2006-10-03 Medarex, Inc. Prodrug compounds with an isoleucine
CA2447023A1 (en) * 2001-05-23 2002-11-28 Dendreon San Diego Llc Conjugates activated by cell surface proteases and therapeutic uses thereof
ATE504315T1 (de) * 2001-06-11 2011-04-15 Medarex Inc Methode für die ausarbeitung von cd10-aktivierten prodrug-verbindungen
CA2470643C (en) * 2001-12-17 2011-10-18 Bryan Paul Morgan Cleavable reagents for specific delivery to disease sites
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
JP4511805B2 (ja) * 2002-04-26 2010-07-28 武田薬品工業株式会社 ネプリライシンの活性測定法
US20040001801A1 (en) * 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
FR2851471B1 (fr) * 2003-02-24 2006-07-28 Synt Em Composes comprenant au moins une substance active et au moins un vecteur relies par un agent de liaison, leurs utilisations et lesdits agents de liaison
DE10310082A1 (de) * 2003-03-07 2004-09-16 Ktb Tumorforschungsgesellschaft Mbh Protein-bindende Doxorubicin-Peptid-Derivate
US20100113328A1 (en) * 2003-05-29 2010-05-06 The Scripps Research Institute Targeted delivery to legumain-expressing cells
US20070167353A1 (en) * 2003-10-24 2007-07-19 John Hilfinger Prodrug composition
US20050137141A1 (en) * 2003-10-24 2005-06-23 John Hilfinger Prodrug composition
JP4654418B2 (ja) 2004-03-31 2011-03-23 独立行政法人産業技術総合研究所 上皮系細胞増殖促進剤
JP2007099750A (ja) * 2005-02-25 2007-04-19 Hokkaido Univ 腫瘍組織で選択的に分解性を示す血中滞留性素子
WO2006124711A1 (en) * 2005-05-16 2006-11-23 The Board Of Trustees Of The University Of Illinois Composition and method for providing localized delivery of a therapeutic agent
CN101374856A (zh) * 2005-11-29 2009-02-25 斯克里普斯研究学院 抑制肿瘤细胞浸润、转移和血管生成
US8962697B2 (en) * 2006-06-30 2015-02-24 Interface Biologics Inc. Bioreponsive polymers
EP1977765A1 (en) * 2007-04-03 2008-10-08 Diatos Peptide prodrugs
GB0707034D0 (en) 2007-04-12 2007-05-23 St Andrews The Compounds
GB0819287D0 (en) * 2008-10-22 2008-11-26 Univ Bradford Compounds
ITUD20130024A1 (it) 2013-02-22 2014-08-23 Carlo Galli Aptameri per la realizzazione di dispositivi biomedicali impiantabili in tessuto e relativo metodo
WO2014145242A1 (en) * 2013-03-15 2014-09-18 The Board Of Trustees Of The University Of Illinois Peptide-coated polymer carriers
GB2516882A (en) 2013-08-02 2015-02-11 Univ Bradford Tumour-targeted theranostic
CN111000988A (zh) * 2013-08-26 2020-04-14 健康研究公司 用于预防和/或治疗ErbB2阳性癌症的方法
EP3183342B1 (en) 2014-08-20 2021-05-12 Health Research, Inc. Method for prophylaxis and/or treatment of erbb1 positive cancers
EP2995612A1 (en) * 2014-09-12 2016-03-16 Université de Strasbourg Novel non-natural amino acids, their process of preparation and uses thereof
TW201920234A (zh) 2017-09-11 2019-06-01 美商領導醫療有限公司 類鴉片促效劑肽及其用途
TW202116356A (zh) * 2019-07-10 2021-05-01 美商斯布雷克薩三號公司 作為治療劑之微管靶向藥劑之肽結合物
EP4262880A1 (en) 2020-12-21 2023-10-25 Cornell University Peptide-linked drug delivery system
CN116635054A (zh) 2020-12-22 2023-08-22 科比欧尔斯公司 包括四肽部分的化合物
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety
CN113876968B (zh) * 2021-10-29 2023-06-09 上海市第一人民医院 Mmp9响应的t1/t2切换型mr纳米探针及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4466919A (en) 1982-12-16 1984-08-21 Monsanto Company Peptide substrates for mammalian collagenase
FR2546163B1 (fr) 1983-05-16 1987-10-09 Centre Nat Rech Scient Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application
US5135736A (en) 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5618528A (en) * 1994-02-28 1997-04-08 Sterling Winthrop Inc. Biologically compatible linear block copolymers of polyalkylene oxide and peptide units
US6143864A (en) 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
US5866679A (en) 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
PT769967E (pt) * 1994-08-19 2008-02-18 Univ Catholique Louvain Conjugados que compreendem um agente antitumoral e a sua utilização
JP2000506494A (ja) 1995-10-18 2000-05-30 メルク エンド カンパニー インコーポレーテッド 良性前立腺過形成の治療に有用な複合体
WO1997048725A1 (en) 1996-06-21 1997-12-24 Peptech Limited Novel peptides for prevention and treatment of infection
CA2265484C (en) 1996-09-10 2008-12-02 The Burnham Institute Tumor homing molecules, conjugates derived therefrom, and methods of using same
EP0926955A4 (en) 1996-09-12 2003-05-07 Merck & Co Inc Conjugates useful in the treatment of prostate cancer
ATE244572T1 (de) 1996-10-15 2003-07-15 Liposome Co Inc Peptid-lipid konjugate, liposomen und liposomale arzneimittelverabreichung
HRP970566A2 (en) 1996-10-30 1998-08-31 Jones Deborah Defeo Conjugates useful in the treatment of prostate canser
EP1005357A1 (en) 1997-04-14 2000-06-07 The Regents Of The University Of California Peptide antiestrogen compositions and methods for treating breast cancer
CA2295860A1 (en) * 1997-07-10 1999-01-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US5965119A (en) * 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
EP1144011B1 (en) 1998-12-11 2010-03-10 Coulter Pharmaceutical, Inc. Prodrug compounds and process for preparation thereof
WO2000059930A1 (en) 1999-04-05 2000-10-12 Merck & Co., Inc. A method of treating cancer
AU772074B2 (en) 1999-04-28 2004-04-08 Vectramed, Inc. Enzymatically activated polymeric drug conjugates
US6613879B1 (en) 1999-05-14 2003-09-02 Boehringer Ingelheim Pharma Kg FAP-activated anti-tumour compounds
WO2000069472A2 (en) * 1999-05-14 2000-11-23 Boehringer Ingelheim Pharmaceuticals, Inc. Enzyme-activated anti-tumor prodrug compounds

Also Published As

Publication number Publication date
BR0109266A (pt) 2003-04-29
SK12872002A3 (sk) 2003-05-02
AU4583601A (en) 2001-09-24
CA2401873A1 (en) 2001-09-20
EP1263473A2 (en) 2002-12-11
CN1418112A (zh) 2003-05-14
WO2001068145A2 (en) 2001-09-20
JP2003526683A (ja) 2003-09-09
MXPA02009019A (es) 2003-02-12
CZ20022998A3 (cs) 2003-05-14
WO2001068145A3 (en) 2002-07-11
PL360826A1 (en) 2004-09-20
AU2001245836A1 (en) 2002-07-16
RU2002127425A (ru) 2004-03-27
IL151400A0 (en) 2003-04-10
NO20024238D0 (no) 2002-09-05
HUP0300590A2 (hu) 2003-07-28
TR200202183T2 (tr) 2007-01-22
KR20030009388A (ko) 2003-01-29
US6844318B2 (en) 2005-01-18
US20020103133A1 (en) 2002-08-01

Similar Documents

Publication Publication Date Title
EE200200522A (et) Toimeainega konjugeerunud ensüüm-lõhustuv peptiid, seda sisaldav farmatseutiline kompositsioon ningühendi kasutamine kasvajavastase ravimina
DZ3227A1 (fr) Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees
IL163552A (en) Conjugates of biologically active compounds, uses thereof and pharmaceutical compositions comprising the same
ITTO20010005A1 (it) Formulazione farmaceutica.
NO20022970L (no) Hydrogel-drevet medikamentdoseringsform
BR0115810B1 (pt) composições cosméticas, dermatológicas e farmacêuticas isentas de tensoativos.
NO20030627L (no) Hydrogel-drevet medikament doseringsform
IL161940A0 (en) Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient
DK1208864T4 (da) Forbedringer til lægemiddelafgivelsesindretninger
ITMI20001173A0 (it) Composizioni farmaceutiche a rilascio prolungato per la somministrazione parenterale di sostanze idrofile biologicamente attiva.
EE200300240A (et) Arüülitud furaan- ja tiofeenkarboksamiid, seda sisaldav ravimpreparaat ning ühendi kasutamine kaaliumikanali blokaatorina toimiva ravimi valmistamiseks
IL163866A0 (en) 8-Azaprostaglandin derivative compounds and drugs containing the compounds s active ingredient
HUP0303653A3 (en) Tricyclic and heterocyclic derivative and pharmaceutical compositions containing them as the active ingredient
IL164699A0 (en) Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredient
ATE354362T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
DE69923336D1 (de) Oral anzuwendende buprenorphinhaltige arzneimittel
ZA200308221B (en) Pharmaceutical compositions for oral and topical administration.
DK1225902T3 (da) Ciclesonidholdigt farmaceutisk præparat til administration til slimhinden
HUP0303673A3 (en) Piperidine derivatives and pharmaceutical compositions containing these derivatives as the active ingredient
AU2001277738A1 (en) Piperidine derivatives and drugs containing these derivatives as the active ingredient
HUP0201696A3 (en) Cyclic peptides, pharmaceutical compositions comprising thereof and their use
AU2001260089A1 (en) Pharmaceutical compositions comprising desglymidodrine as an active drug substance
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
AR025867A1 (es) Formulacion portasdora farmaceutica
EE200200480A (et) Memnopeptiidühend, selle valmistamine ja raviotstarbeline kasutamine ning seda sisaldav farmatseutiline kompositsioon
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载